Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of a standardized treatment regimen for acromegaly
2010-023674-39Phase 4Completed
- Sponsor
- Österreichisches Akromegalie Register
- Start
- Jul 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanreotide, octreotide and pegvisomant in acromegaly, sponsored by Österreichisches Akromegalie Register. Primary endpoint: Normalization of IGF-1. Started Jul 2014; status: completed.
02
Drugs
lanreotideoctreotidepegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2010-023674-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023674-39.